Glox Development Program
Infections caused by drug-resistant Gram-negative bacteria (e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae)
Pre-clinicalActive
Key Facts
Indication
Infections caused by drug-resistant Gram-negative bacteria (e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae)
Phase
Pre-clinical
Status
Active
Company
About Glox Therapeutics
Glox Therapeutics is an Oxford, UK-based biotech developing a novel class of precision antibiotics called engineered bacteriocins to address the critical global threat of antimicrobial resistance. Built on a proprietary discovery platform derived from two decades of academic research, the company is advancing a pipeline targeting high-priority, multidrug-resistant Gram-negative pathogens. As a private, preclinical-stage company, Glox aims to deliver targeted, narrow-spectrum therapeutics that could overcome existing resistance mechanisms and improve patient outcomes in serious hospital-acquired infections.
View full company profile